Literature DB >> 18215695

Variation in age at ESRD in autosomal dominant polycystic kidney disease.

Berenice Y Reed1, Kim McFann, Mir R Bekheirnia, M Reza Bekheirnia, Niloofar Nobakhthaghighi, Niloofar Nobkhthaghighi, Amirali Masoumi, Ann M Johnson, Alireza A Shamshirsaz, Alireza Abdollah Shamshiraz, Catherine L Kelleher, Robert W Schrier.   

Abstract

BACKGROUND: Heterogeneity manifest as more severe disease in successive generations has been attributed to genetic anticipation in patients with autosomal dominant polycystic kidney disease (ADPKD). We evaluated variation in age at end-stage renal disease (ESRD) in ADPKD families for evidence of anticipation. STUDY
DESIGN: Retrospective. SETTING & PARTICIPANTS: 413 families with ADPKD seen at our single center between 1985 and 2004 (including 95 families with documented polycystic disease type 1 [PKD1] and 213 ADPKD families with parents born before 1930). PREDICTOR: Generational status. OUTCOME: Age at ESRD onset. MEASUREMENTS: Time to ESRD was evaluated by using survival analysis, Cox regression, and descriptive statistics. Unstable trinucleotide repeat expansion was evaluated by means of genotyping in 6 PKD1 families.
RESULTS: We analyzed 413 ADPKD families (1,391 parent-offspring pairs) with known age at ESRD or last known age without ESRD (informative pairs). There was no difference in age at ESRD between parents and offspring by means of Cox regression after adjusting for correlations among family members and sex (hazard ratio, 1.019; 95% confidence interval, 0.919 to 1.13; P = 0.7). Similar analysis of PKD1 informative pairs and those with parents born before 1930 showed no differences in age at ESRD. Male ADPKD patients were 42% more likely to reach ESRD (P < 0.001), and male patients with documented PKD1 were 41% more likely to reach ESRD (P = 0.01) than female patients. LIMITATIONS: Hypertension treatment unknown.
CONCLUSIONS: We found no evidence for anticipation of ESRD in patients with ADPKD; thus, the observed variation in age at ESRD may result from other genetic, sex, or environmental causes.

Entities:  

Mesh:

Year:  2008        PMID: 18215695      PMCID: PMC2747334          DOI: 10.1053/j.ajkd.2007.10.037

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  24 in total

1.  Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n.

Authors:  E J Kremer; M Pritchard; M Lynch; S Yu; K Holman; E Baker; S T Warren; D Schlessinger; G R Sutherland; R I Richards
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

2.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

3.  Anticipation in myotonic dystrophy: fact or fiction?

Authors:  C J Höweler; H F Busch; J P Geraedts; M F Niermeijer; A Staal
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

4.  Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.

Authors:  P A Gabow; A M Johnson; W D Kaehny; W J Kimberling; D C Lezotte; I T Duley; R H Jones
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

5.  A complete mutation screen of the ADPKD genes by DHPLC.

Authors:  Sandro Rossetti; Dominique Chauveau; Denise Walker; Anand Saggar-Malik; Christopher G Winearls; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

6.  Anticipation in myotonic dystrophy: new light on an old problem.

Authors:  P S Harper; H G Harley; W Reardon; D J Shaw
Journal:  Am J Hum Genet       Date:  1992-07       Impact factor: 11.025

7.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1.

Authors:  H T Orr; M Y Chung; S Banfi; T J Kwiatkowski; A Servadio; A L Beaudet; A E McCall; L A Duvick; L P Ranum; H Y Zoghbi
Journal:  Nat Genet       Date:  1993-07       Impact factor: 38.330

8.  Autosomal dominant polycystic kidney disease in childhood: a longitudinal study.

Authors:  A Sedman; P Bell; M Manco-Johnson; R Schrier; B A Warady; E O Heard; N Butler-Simon; P Gabow
Journal:  Kidney Int       Date:  1987-04       Impact factor: 10.612

9.  Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Authors:  Robert Schrier; Kimberly McFann; Ann Johnson; Arlene Chapman; Charles Edelstein; Godela Brosnahan; Tevfik Ecder; Lyn Tison
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  Anticipation in Huntington's disease is inherited through the male line but may originate in the female.

Authors:  R M Ridley; C D Frith; T J Crow; P M Conneally
Journal:  J Med Genet       Date:  1988-09       Impact factor: 6.318

View more
  18 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 3.  Molecular diagnostics for autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Kidney: polycystic kidney disease.

Authors:  Binu M Paul; Gregory B Vanden Heuvel
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2014-09-03       Impact factor: 5.814

Review 5.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

6.  The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.

Authors:  Berenice Reed; Imed Helal; Kim McFann; Wei Wang; Xiang-Dong Yan; Robert W Schrier
Journal:  Nephrol Dial Transplant       Date:  2011-12-29       Impact factor: 5.992

7.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

8.  Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.

Authors:  Berenice Reed; Kim McFann; William J Kimberling; York Pei; Patricia A Gabow; Karen Christopher; Eric Petersen; Catherine Kelleher; Pamela R Fain; Ann Johnson; Robert W Schrier
Journal:  Am J Kidney Dis       Date:  2008-07-21       Impact factor: 8.860

9.  A Report of the 24th Annual Congress on Women's Health-Workshop on Transforming Women's Health: From Research to Practice.

Authors:  Jennifer L Plank-Bazinet; Annie Sampson; Susan G Kornstein; Gregory G Germino; Marjorie Robert-Guroff; Stephen E Gilman; Cora Lee Wetherington; Nakela Cook; Terri L Cornelison; Lisa Begg; Janine Austin Clayton
Journal:  J Womens Health (Larchmt)       Date:  2018-01       Impact factor: 2.681

Review 10.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.